Sayeda Yasmin-Karim, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiation, Ionizing | 1 | 2018 | 258 | 0.610 |
Why?
|
Biocompatible Materials | 2 | 2021 | 1736 | 0.520 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2014 | 185 | 0.480 |
Why?
|
Sialoglycoproteins | 1 | 2014 | 318 | 0.470 |
Why?
|
Cancer Vaccines | 1 | 2018 | 1024 | 0.380 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2014 | 933 | 0.320 |
Why?
|
Antibodies, Monoclonal | 2 | 2018 | 9275 | 0.240 |
Why?
|
Radioimmunotherapy | 1 | 2021 | 91 | 0.200 |
Why?
|
Pancreatic Neoplasms | 1 | 2018 | 5257 | 0.190 |
Why?
|
Plant Leaves | 1 | 2020 | 143 | 0.170 |
Why?
|
CD8-Positive T-Lymphocytes | 3 | 2023 | 4477 | 0.160 |
Why?
|
Graphite | 1 | 2018 | 66 | 0.160 |
Why?
|
Tumor Burden | 2 | 2021 | 1914 | 0.160 |
Why?
|
Vitamin D | 4 | 2012 | 3222 | 0.150 |
Why?
|
Neoplasms | 3 | 2023 | 21672 | 0.150 |
Why?
|
Fiducial Markers | 1 | 2018 | 136 | 0.150 |
Why?
|
Prostatic Neoplasms | 4 | 2014 | 11074 | 0.150 |
Why?
|
Oxides | 1 | 2018 | 405 | 0.140 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2018 | 876 | 0.140 |
Why?
|
Carcinoma, Lewis Lung | 1 | 2016 | 114 | 0.140 |
Why?
|
Plant Extracts | 1 | 2020 | 472 | 0.140 |
Why?
|
Metal Nanoparticles | 1 | 2020 | 405 | 0.130 |
Why?
|
Nanoparticles | 2 | 2016 | 1905 | 0.130 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2016 | 358 | 0.120 |
Why?
|
Titanium | 1 | 2016 | 494 | 0.110 |
Why?
|
Nanostructures | 1 | 2018 | 551 | 0.110 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2018 | 1372 | 0.110 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 1039 | 0.110 |
Why?
|
Receptors, Calcitriol | 2 | 2011 | 350 | 0.100 |
Why?
|
Photosensitizing Agents | 1 | 2016 | 602 | 0.100 |
Why?
|
Receptor Cross-Talk | 1 | 2011 | 119 | 0.100 |
Why?
|
Oxygen | 1 | 2023 | 4187 | 0.100 |
Why?
|
Adjuvants, Immunologic | 1 | 2016 | 1001 | 0.100 |
Why?
|
Mice | 7 | 2021 | 81178 | 0.090 |
Why?
|
Cell Adhesion | 2 | 2014 | 3144 | 0.090 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2018 | 3557 | 0.090 |
Why?
|
Hematopoiesis | 1 | 2020 | 2069 | 0.090 |
Why?
|
Cell Line, Tumor | 5 | 2020 | 16687 | 0.090 |
Why?
|
Tumor Microenvironment | 1 | 2021 | 3584 | 0.080 |
Why?
|
Radiotherapy | 1 | 2016 | 1525 | 0.080 |
Why?
|
Radiosurgery | 1 | 2018 | 1328 | 0.080 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2011 | 560 | 0.080 |
Why?
|
Endothelium | 1 | 2011 | 778 | 0.080 |
Why?
|
Neoplasm Metastasis | 2 | 2018 | 4841 | 0.080 |
Why?
|
Molecular Targeted Therapy | 1 | 2018 | 2727 | 0.070 |
Why?
|
Neoplasm Invasiveness | 1 | 2014 | 3614 | 0.070 |
Why?
|
Combined Modality Therapy | 1 | 2018 | 8628 | 0.070 |
Why?
|
Animals | 7 | 2021 | 168788 | 0.070 |
Why?
|
Lung Neoplasms | 2 | 2020 | 13096 | 0.060 |
Why?
|
Immunotherapy | 1 | 2018 | 4440 | 0.050 |
Why?
|
Cell Movement | 1 | 2014 | 5216 | 0.050 |
Why?
|
Down-Regulation | 1 | 2010 | 3001 | 0.050 |
Why?
|
Tumor Suppressor Proteins | 1 | 2011 | 2848 | 0.050 |
Why?
|
NF-kappa B | 1 | 2010 | 2501 | 0.050 |
Why?
|
Immunohistochemistry | 1 | 2014 | 11368 | 0.050 |
Why?
|
Cell Cycle Proteins | 1 | 2011 | 3461 | 0.050 |
Why?
|
Disease Models, Animal | 1 | 2018 | 18027 | 0.040 |
Why?
|
Erythrocyte Indices | 1 | 2020 | 146 | 0.040 |
Why?
|
Carcinoembryonic Antigen | 1 | 2020 | 347 | 0.040 |
Why?
|
Immunity | 1 | 2023 | 1012 | 0.040 |
Why?
|
Gold | 1 | 2020 | 484 | 0.040 |
Why?
|
MicroRNAs | 1 | 2012 | 3747 | 0.040 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2020 | 1574 | 0.030 |
Why?
|
Male | 7 | 2021 | 350027 | 0.030 |
Why?
|
Treatment Outcome | 2 | 2018 | 63119 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2011 | 9647 | 0.030 |
Why?
|
Hemoglobins | 1 | 2020 | 1533 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2020 | 2204 | 0.030 |
Why?
|
Methylnitrosourea | 1 | 2011 | 29 | 0.030 |
Why?
|
Acid Anhydride Hydrolases | 1 | 2011 | 72 | 0.030 |
Why?
|
Monte Carlo Method | 1 | 2016 | 1254 | 0.020 |
Why?
|
Vaccination | 1 | 2023 | 3278 | 0.020 |
Why?
|
Cell Aggregation | 1 | 2011 | 244 | 0.020 |
Why?
|
3' Untranslated Regions | 1 | 2012 | 513 | 0.020 |
Why?
|
Signal Transduction | 2 | 2011 | 23404 | 0.020 |
Why?
|
Anemia | 1 | 2020 | 1504 | 0.020 |
Why?
|
Rheology | 1 | 2011 | 345 | 0.020 |
Why?
|
Antineoplastic Agents | 1 | 2012 | 13668 | 0.020 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 2010 | 821 | 0.020 |
Why?
|
Brachytherapy | 1 | 2016 | 1246 | 0.020 |
Why?
|
Chemokine CXCL12 | 1 | 2011 | 464 | 0.020 |
Why?
|
E-Selectin | 1 | 2011 | 579 | 0.020 |
Why?
|
Drug Synergism | 1 | 2012 | 1791 | 0.020 |
Why?
|
Cell Survival | 1 | 2018 | 5881 | 0.020 |
Why?
|
Humans | 9 | 2023 | 744220 | 0.020 |
Why?
|
Recurrence | 1 | 2018 | 8343 | 0.020 |
Why?
|
Microvessels | 1 | 2011 | 544 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2016 | 5076 | 0.020 |
Why?
|
Cadherins | 1 | 2011 | 907 | 0.020 |
Why?
|
Cell Line | 1 | 2020 | 15999 | 0.020 |
Why?
|
Mice, Nude | 1 | 2011 | 3689 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2011 | 8426 | 0.020 |
Why?
|
Cell Cycle | 1 | 2012 | 2967 | 0.020 |
Why?
|
Female | 2 | 2020 | 380197 | 0.010 |
Why?
|
DNA Repair | 1 | 2011 | 2046 | 0.010 |
Why?
|
DNA Damage | 1 | 2011 | 2432 | 0.010 |
Why?
|
Lung | 1 | 2020 | 9852 | 0.010 |
Why?
|
Oxidative Stress | 1 | 2011 | 3085 | 0.010 |
Why?
|
Phosphorylation | 1 | 2011 | 8437 | 0.010 |
Why?
|
Protein Binding | 1 | 2012 | 9392 | 0.010 |
Why?
|
Antigens, CD | 1 | 2011 | 4026 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2012 | 9735 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2016 | 21824 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2012 | 7723 | 0.010 |
Why?
|
Endothelial Cells | 1 | 2011 | 3478 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2010 | 3703 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2012 | 10480 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2011 | 13036 | 0.010 |
Why?
|
Mutation | 1 | 2011 | 29784 | 0.000 |
Why?
|